Within the Chronic Inflammatory Demyelinating Polyneuropathy Market segment, the market is primarily segmented by Treatment Type into Intravenous Immunoglobulin (IVIg), Corticosteroids, Immunosuppressive Therapy, and Plasmapheresis. IVIg holds a commanding position due to its efficacy and status as a first-line treatment, contributing the largest revenue share.

In terms of End-Users, the Chronic Inflammatory Demyelinating Polyneuropathy Market segment is divided among Hospitals, Research Institutions, and Homecare Settings. The shift towards Homecare Settings, facilitated by user-friendly SCIg products, represents a key growth area for manufacturers seeking to improve convenience and reduce hospitalization costs.